VUNO Med
DeepBrain
Key Features
MFDS(K-FDA) Approved CE Certified
®
®
Why VUNO Med®-DeepBrain®?
Agnostic to Any Device
UI design is primarily focused on user’s
convenience. Easy to use without much
time required for adaptation.
PACS Integration available depending on
the clinical environment. Easily integrated
to the current workflow.
Cost & Time Efficient
DeepBrain provides quantitiative data on
brain parcellation within a minute.
Additional analysis tool with furthe
viewer programs is not necessary.
Autonomous &
Clinically Aligned
It can be a supporting tool for diagnosis
of neurodegenerative diseases such as
Alzheimer’s Disease based on normative
percentile score and volume information
for 100+ brain areas.
Patient satisfaction can be improved by
providing the Brian Atrophy Report with
the statistical analysis results an
visualized graphs.
Internal retrospective study4) Ochs AL, et al. Comparison of Automated Brain Volume
Measures obtained with NeuroQuant and FreeSurfer. J Neuroimaging. 2015 Sep-
Oct;25(5):721-7
Ochs AL, et al. Comparison of Automated Brain Volume Measures obtained with
NeuroQuant and FreeSurfer. J Neuroimaging. 2015 Sep-Oct;25(5):721-7.
Brain Volumetry
Provides quantitative information of
brain atrophy through the analyzed
volumetric data of 100+ regions through
brain parcellation
Supports longitudinal tracking to monitor
volumetric changes
DeepBrain provides
Volume(ml)
% of ICV
Normative Percentile
Regional volumes
Ratio of the specific area volume to the
intracranial volume (ICV)
Rank percentage among the normal
population. Less normative percentile
indicates smaller volume of a specific region
compared to the clinical normal population
with the same sex and age.
VUNO Med–DeepBrain reported high consistency with
FreeSurfer(reference standard) for almost all brain
regions and this consistency is especially higher for
small brain regions like putamen and pallidum.1,2
**FreeSurfer
A software package for the analysis and visuali
z
ation of structural and
functional neuroimaging data from cross-sectional or longitudinal studies.
Brain Volumetry
UI Example
Report Example*
*The report also provides Volumetric information on
cerebral white matter, subcortical grey matter, ventricle,
cerebellum, and brainstem.
Longitudinal Analysis
During the normal aging process brain volume
decreases gradually, but if the brain atrophies
significantly over a short period of time, a thorough
examination may be needed to identify the cause. By
comparing the individual's brain atrophy rate with
normal brain atrophy rate and administering continuous
subsequent analysis, appropriate preventative
measures can be implemented alongside treatment
plans.
Sample Longitudinal Analysis Report
Longitudinal Analysis
Atrophy Score4
Atrophy Scoring System
MTA Score (Schelten’s Scale)
3
Capturing Atrophy in Medical Temporal Lobe
Indicates an AI-based Quantification of Brain Atrophy
The brain atrophy score helps patients understand
their condition and can serve as a guide to seek
consultation from a specialist on preventive measures
and/or inverventions, if needed.
Scheltens, Philip, et al. "Atrophy of medial temporal lobes on MRI in" probable"
Alzheimer's disease and normal ageing: diagnostic value and neuropsychological
correlates."Journal of Neurology, Neurosurgery & Psychiatry55.10 (1992): 967-97 2.
Suh, C. H., et al. "Development and validation of a deep learning–based automatic
brain segmentation and classification algorithm for Alzheimer disease using 3D T1-
weighted volumetric images." American Journal of Neuroradiology41.12 (2020):
2227-2234.
Cortical Thickness Measurement
Provides data on cortical thickness and
normative percentile
Visualizes the cortical thickness data and
location through Color Map
UI Example
Report Example
Short processing time (5 to 10 seconds)
The reference table of qualitative
formulation of Fazekas scale6
White Matter Hyperintensity
Quantification
White matter hyperintensities (WMHs) in
the brain are the consequence of
cerebral white matter ischemic lesions
Provides quantitative data on WMH
volume when T2-FLAIR image is
uploaded.
Automatically computes Fazekas scale
to quantify amount of white matter
lesions.
5
· White matter ischemic lesions could a result of
subcortical vascular dementia(SVD), could worsen
the condition if presented together with AD
· Presence of WMH leads to movement disorder,
stuttering, incontinence, cognitive disability
Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at
1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987
Aug;149(2):351-6. doi: 10.2214/ajr.149.2.351. PMID: 3496763.
Noh, Young, et al. "A new classification system for ischemia using a combination of
deep and periventricular white matter hyperintensities."Journal of Stroke and
Cerebrovascular Diseases23.4 (2014): 636-642.
Case Review Case 1
Key Findings
Diagnosis
High brain atrophy score, low normative
percentiles in temporal lobe regions.
Alzheimer’s Disease
Age 72 Sex Female MMSE 16
Years of cognitive impairment
Courtesy of Prof. Chong Hyun Suh, Department of Radiology, Asan Medical Centre
Case Review Case 2
Key Findings
Diagnosis
Abnormal atrophies in several temporal and
frontal regions (2019), progressed atrophies and
increased MTA score (2021)
Nonfluent-variant primary progressive aphasia
Age 63 Sex Male
2019-08-05
2021-03-07
MMSE 19
Courtesy of Prof. Chong Hyun Suh, Department of Radiology, Asan Medical Centre
MTA Score
MTA Score
Case Review Case 3
Key Findings
Diagnosis
Low normative percentiles of temporal lobe
volumes and cortical thickness, high brain
atrophy score
Early-onset Alzheimer’s Disease
Age 56 Sex Male MMSE 13
Courtesy of Prof. Chong Hyun Suh, Department of Radiology, Asan Medical Centre
3 years of cognitive impairment
Case Review Case 4
Diagnosis
Mixed Dementi
(Alzheimer’s Disease+Vascular Dementia)
Age 75 Sex Female MMSE 16
Courtesy of Prof. Chong Hyun Suh, Department of Radiology, Asan Medical Centre
Cognitive impairment
Key Findings
Atrophy in temporal lobe, large amount of white
matter hyperintensities
